Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005070|
Recruitment Status : Completed
First Posted : August 9, 2004
Last Update Posted : June 19, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IVB or recurrent cervical cancer.
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer||Drug: irofulven||Phase 2|
OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene in patients with stage IVB or recurrent cervical carcinoma. II. Determine the safety of this drug in this patient population.
OUTLINE: Patients receive 6-hydroxymethylacylfulvene IV over 5 minutes daily for 5 consecutive days. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma|
|Study Start Date :||January 2000|
|Actual Primary Completion Date :||May 2001|
|Actual Study Completion Date :||May 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005070
|Study Chair:||Carol Aghajanian, MD||Memorial Sloan Kettering Cancer Center|